144 related articles for article (PubMed ID: 2902683)
1. Comparative haemodynamic effects of betaxolol and propranolol in patients with cirrhosis.
Braillon A; Lee SS; Valla D; Geoffroy P; Sauvanet JP; Lebrec D
Scand J Gastroenterol; 1988 Aug; 23(6):691-5. PubMed ID: 2902683
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the short-term effects of mepindolol and propranolol on splanchnic and systemic haemodynamics in patients with cirrhosis.
Braillon A; Calès P; Lebrec D
Int J Clin Pharmacol Res; 1985; 5(4):223-8. PubMed ID: 4055165
[TBL] [Abstract][Full Text] [Related]
3. Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new beta-blocker with nitrovasodilating properties, in patients with portal hypertension due to cirrhosis. A comparative study with propranolol.
Aramaki T; Sekiyama T; Katsuta Y; Kurokawa H; Komeichi H; Tsutsui H; Terada H; Ohsuga M; Satomura K; Okumura H
J Hepatol; 1992 May; 15(1-2):48-53. PubMed ID: 1354676
[TBL] [Abstract][Full Text] [Related]
4. Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomised study.
Hobolth L; Bendtsen F; Hansen EF; Møller S
Dig Liver Dis; 2014 Mar; 46(3):251-6. PubMed ID: 24290869
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic prevention of variceal bleeding and rebleeding.
Baiges A; Hernández-Gea V; Bosch J
Hepatol Int; 2018 Feb; 12(Suppl 1):68-80. PubMed ID: 29210030
[TBL] [Abstract][Full Text] [Related]
6. Haemodynamic effects of propranolol, octreotide and their combination during fasting and post-prandial splanchnic hyperaemia in patients with cirrhosis.
Sabbà C; Buonamico P; Vendemiale G; Berardi E; Antonica G; Palmieri V; Merkel C; Palasciano G
Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):163-9. PubMed ID: 11246616
[TBL] [Abstract][Full Text] [Related]
7. Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis.
Mastai R; Bosch J; Navasa M; Kravetz D; Bruix J; Viola C; Rodés J
J Hepatol; 1987 Feb; 4(1):71-9. PubMed ID: 3033061
[TBL] [Abstract][Full Text] [Related]
8. Propranolol plus molsidomine vs propranolol alone in the treatment of portal hypertension in patients with cirrhosis.
García-Pagán JC; Escorsell A; Feu F; Bandi JC; Moitinho E; Casado M; Bosch J; Rodés J
J Hepatol; 1996 Apr; 24(4):430-5. PubMed ID: 8738729
[TBL] [Abstract][Full Text] [Related]
9. Hyperkinetic circulatory syndrome in patients with presinusoidal portal hypertension. Effect of propranolol.
Braillon A; Moreau R; Hadengue A; Roulot D; Sayegh R; Lebrec D
J Hepatol; 1989 Nov; 9(3):312-8. PubMed ID: 2607120
[TBL] [Abstract][Full Text] [Related]
10. Acute effect of propranolol on splanchnic circulation in normal and portal hypertensive rats.
Calès P; Braillon A; Girod C; Lebrec D
J Hepatol; 1985; 1(4):349-57. PubMed ID: 4056347
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic effects of nipradilol, a new beta-adrenergic antagonist combined with a nitroxy base, in rats with intra- or extra-hepatic portal hypertension.
Ohsuga M; Cailmail S; Lebrec D
J Hepatol; 1993 Feb; 17(2):236-40. PubMed ID: 8095275
[TBL] [Abstract][Full Text] [Related]
12. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis.
Sinagra E; Perricone G; D'Amico M; Tinè F; D'Amico G
Aliment Pharmacol Ther; 2014 Mar; 39(6):557-68. PubMed ID: 24461301
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of a cardioselective and a nonselective beta-blocker on portal hypertension in patients with cirrhosis.
Hillon P; Lebrec D; Muńoz C; Jungers M; Goldfarb G; Benhamou JP
Hepatology; 1982; 2(5):528-31. PubMed ID: 7118065
[TBL] [Abstract][Full Text] [Related]
14. Selective and non-selective beta receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension.
Westaby D; Bihari DJ; Gimson AE; Crossley IR; Williams R
Gut; 1984 Feb; 25(2):121-4. PubMed ID: 6693039
[TBL] [Abstract][Full Text] [Related]
15. Effects of propranolol on portal hemodynamics in patients with chronic liver disease.
Ohnishi K; Nakayama T; Saito M; Hatano H; Tsukamoto T; Terabayashi H; Sugita S; Wada K; Nomura F; Koen H
Am J Gastroenterol; 1985 Feb; 80(2):132-5. PubMed ID: 3881933
[TBL] [Abstract][Full Text] [Related]
16. Portal pressure response to losartan compared with propranolol in patients with cirrhosis.
De BK; Bandyopadhyay K; Das TK; Das D; Biswas PK; Majumdar D; Mandal SK; Ray S; Dasgupta S
Am J Gastroenterol; 2003 Jun; 98(6):1371-6. PubMed ID: 12818283
[TBL] [Abstract][Full Text] [Related]
17. A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients.
Castaño G; Viudez P; Riccitelli M; Sookoian S
Ann Hepatol; 2003; 2(1):36-40. PubMed ID: 15094704
[TBL] [Abstract][Full Text] [Related]
18. Reductions in portal pressure by selective beta 2-adrenoceptor blockade in patients with cirrhosis and portal hypertension.
Bihari D; Westaby D; Gimson A; Crossley I; Harry J; Williams R
Br J Clin Pharmacol; 1984 Jun; 17(6):753-7. PubMed ID: 6146330
[TBL] [Abstract][Full Text] [Related]
19. Effect of nadolol on liver haemodynamics and function in patients with cirrhosis.
Merkel C; Sacerdoti D; Finucci GF; Zuin R; Bazzerla G; Bolognesi M; Gatta A
Br J Clin Pharmacol; 1986 Jun; 21(6):713-9. PubMed ID: 3741719
[TBL] [Abstract][Full Text] [Related]
20. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J
Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
